- Déficit Androgénique
- Prostate et Androgène Lié à l’Âge
- Published:
Testostérone circulante et cancer de la prostate. Revue de données récentes
Circulating testosterone and prostate cancer. A brief review
Andrologie volume 14, pages 381–387 (2004)
Resume
Des étudesin vitro etin vivo ont monté que les androgènes stimulent le cancer de la prostate. Cependant les études épidémiologiques n’ont pas mis clairement en évidence d’association entre les niveaux circulants d’androgènes et le risque de cancer de la prostate. Toutefois la plupart des études n’avaient pas la taille requise pour mettre en évidence un lien qui peut être relativement faible.
Les études prospectives de l’association entre la concentration sérique de testostérone libre et totale, le principal androgène circulant, et le risque de cancer de la prostate ont été revues.
II n’a pas été mis en évidence d’association significative entre la testostérone libre ou la testostérone totale et le risque de cancer de la prostate dans des études qui totalisent 1 525 cas de cancer de la prostate et 4349 sujets témoins. II n’y a pas d’argument pour défendre l’hypothèse selon laquelle, des concentrations élevées de testostérone dans la gamme physiologique, stimulent le développement et la croissance du cancer de la prostate. Le métabolisme intraprostatique des androgènes peut néanmoins être important pour le développement du cancer de la prostate.
Abstract
In vitro andin vivo studies show that androgens stimulate prostate cancer. However, evidence from epidemiological studies of an association between circulating levels of androgens and prostate cancer risk has been inconsistent, but most studies have likely been undersized given that the association may be relatively weak.
We review prospective studies on the association of serum levels of free and total testosterone, the principal androgen in circulation with risk of prostate cancer.
No significant association between total or free testosterone and risk of prostate cancer was found in studies that together included 1,525 cases of prostate cancer and 4,349 controls.
No support was found for the hypothesis that high levels of circulating testosterone within a physiological range stimulate development and growth of prostate cancer. Intraprostatic androgen metabolism may still be of importance for prostate cancer development.
References
ANDERSON D.C., THORNER M.O., FISHER R.A. et al.: Effects of hormonal treatment on plasma unbound androgen levels in hirsute women. Acta Endocrinol. Suppl. (Copenh), 1975, 199: 224.
BIANCHINI F., KAAKS R., VAINIO H.: Overweight, obesity, and cancer risk. Lancet Oncol., 2002, 3: 565–574.
BLADOU F., VESSELA R.L., BUHLER K.R. et al.: Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int. J. Cancer, 1996, 67: 785–790.
BOSLAND M.C.: The role of steroid hormones in prostate carcinogenesis. Journal of the National Cancer Institute Monographs, 2000, 27: 67–73.
CALLE E.E., RODRIGUEZ C., WALKER-THURMOND K. et al.: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 2003, 348: 1625–1638.
DORGAN J.F., ALBANES D., VIRTAMO J. et al.: Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol. Biomarkers Prev., 1998, 7: 1069–1074.
EATON N.E., REEVES G.K., APPLEBY P.N. et al.: Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br. J. Cancer, 1999, 80: 930–934.
GANN P.H., HENNEKENS C.H., MA J. et al.: Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer. Inst., 1996, 88: 1118–1126.
GAPSTUR S.M., GANN P.H., KOPP P. et al.: Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol. Biomarkers Prev., 2002, 11: 1041–1047.
GIOVANNUCCI E., STAMPFER M.J., KRITHIVAS K. et al.: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA, 1997, 94: 3320–3323.
GRUENEWALD D.A., MATSUMOTO A.M.: Testosterone supplementation therapy for older men: potential benefits and risks. J. Am. Geriatr. Soc., 2003, 51: 101–115.
GUESS H.A., FRIEDMAN G.D., SADLER M.C. et al.: 5 alpha-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol. Biomarkers Prev., 1997, 6: 21–24.
HEIKKILA R., AHO K., HELIOVAARA M. et al.: Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer, 1999, 86: 312–315.
HSING A.W., COMSTOCK G.W.: Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol. Biomarkers Prev., 1993, 2: 27–32.
HSING A.W., REICHARDT J.K., STANCZYK F.Z.: Hormones and prostate cancer: current perspectives and future directions. Prostate, 2002, 52: 213–235.
IRANI J., RAVERY V., PARIENTE J.L. et al.: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J. Urol., 2002, 168: 1985–1988.
KAAKS R., LUKANOVA A., SOMMERSBERG B.: Plasma androgens, IGF-I, body size and prostate cancer risk: a synthetic review. Prostate Cancer Prostatic. Dis., 2000, 3: 157–172.
KYPRIANOU N., ENGLISH H.F., ISAACS J.T.: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 1990, 50: 3748–3753.
LUCIA M.S., BOSTWICK D.G., BOSLAND M. et al.: Workgroup I: rodent models of prostate cancer. Prostate, 1998, 36: 49–55.
MAKRIDAKIS N.M., REICHARDT J.K.: Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol. Rev., 2001, 23: 24–29.
MONTGOMERY J.S., PRICE D.K., FIGG W.D.: The androgen receptor gene and its influence on the development and progression of prostate cancer. J. Pathol., 2001, 195: 138–148.
MORALES A.: Androgen replacement therapy and prostate safety. Eur. Urol., 2002, 41: 113–120.
MORLEY J.E., PATRICK P., PERRY H.M.3.: Evaluation of assays available to measure free testosterone. Metabolism, 2002, 51: 554–559.
NAIR B., WILT. T., MACDONALD R. et al.: Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. The Cochrane database of systematic reviews, 2002, Computer File 1: CD003506.
NOMURA A.M., STEMMERMANN G.N., CHYOU P.H. et al.: Serum androgens and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 1996, 5: 621–625.
NORMAN R.W., COAKES K.E., WRIGHT A.S. et al.: Androgen metabolism in men receiving finasteride before prostatectomy. J. Urol., 1993, 150: 1736–1739.
STATTIN P., LUMME S., TENKANEN L. et al.: High levels of circulating testosterone are not associated with increased prostate cancer risk: A pooled prospective study. Int. J. Cancer, 2004, 108: 418–424.
SINNECKER G.: Stability of sex-hormone-binding globulin in serum and plasma. Clin. Chem., 1989, 35: 1253–1254.
THOMPSON I.M., GOODMAN P.J., TANGEN C.M. et al.: The influence of finasteride on the development of prostate cancer. N. Engl. J. Med., 2003, 349: 215–224.
UKKOLA O., GAGNON J., RANKINEN T. et al.: Age, body mass index, race and other determinants of steroid hormone variability: the HERITAGE Family Study. Eur. J. Endocrinol., 2001, 145: 1–9.
VATTEN L.J., URSIN G., ROSS R.K. et al.: Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol. Biomarkers Prev., 1997, 6: 967–969.
VERMEULEN A.: Androgen replacement therapy in the aging male-a critical evaluation. J. Clin. Endocrinol. Metab., 2001, 86: 2380–2390.
VERMEULEN A., VERDONCK G.: Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J. Clin. Endocrinol. Metab., 1992, 74: 939–942.
VERMEULEN A., VERDONCK L., KAUFMAN J.M.: A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 1999, 84: 3666–3672.
WEBBER M.M., BELLO D., QUADER S.: Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines. Prostate, 1996, 29: 386–394.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communication au XXo Congrès de la Société d’Andrologie de Langue Française, Orléans, 11–13 Décembre 2003.
Rights and permissions
About this article
Cite this article
Stattin, P. Testostérone circulante et cancer de la prostate. Revue de données récentes. Androl. 14, 381–387 (2004). https://doi.org/10.1007/BF03035168
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03035168